Industry landscapes
The companies, capital and talent shaping life sciences in Toronto. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
No company example met every recorded classification, independence and public-profile gate in this snapshot. The live directory may have newer qualifying companies.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
28 of 395 tracked companies have open roles.
141 of 395 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 265 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 22.6% of disclosed capital, while 64.3% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $78.44M | 26 | 13 |
| 2017 | $134.29M | 29 | 18 |
| 2018 | $118.16M | 31 | 17 |
| 2019 | $315.26M | 27 | 27 |
| 2020 | $300.04M | 29 | 25 |
| 2021 | $385.96M | 12 | 26 |
| 2022 | $171.2M | 9 | 21 |
| 2023 | $138.43M | 17 | 16 |
| 2024 | $392.27M | 5 | 21 |
| 2025 | $173.68M | 2 | 22 |
Share of all disclosed company funding.
335 recorded rounds since 2016
Recorded participation in life sciences company rounds since 2016.
Backed by Genome Canada and Ontario Genomics.
Backed by .
Backed by SoftBank Vision Fund and CPP Investments and others.
Backed by Novo Holdings and Arkin Holdings and others.
Backed by Guoxin Capital and SBCVC and others.
Backed by Allogene Therapeutics and Lumira Ventures and others.
Backed by Generation Investment Management and Inovia Capital and others.
Backed by Inovia Capital and TCV and others.
Participating investors were not recorded in this snapshot.
Backed by Future Ventures and Amplitude and others.
Backed by Westlake Village Biopartners and Lightspeed Venture Partners.
Backed by EW Healthcare Partners and Health Quest Capital and others.
The measured Canada identity-to-filing probe did not produce a qualifying designated legal or national-ID join: world_filings_distributed exposes no reviewed Canadian national-ID key; none of the designated Canadian identities carried a CIK.; The measured Canada identity-to-filing probe did not produce a qualifying designated legal or national-ID join: world_filings_distributed exposes no reviewed Canadian national-ID key; none of the designated Canadian identities carried a CIK.
How the Toronto companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
7 of these companies (1.8%) publish at least one Android app — 45 apps in all, carrying 72.6K installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| AvicennaAvicenna Research | 40.7K | 4.2 | Tools |
| GAMMA Research StudyAvicenna Research | 9.7K | — | Tools |
| Fusion ePROAxiom Real-Time Metrics | 7.4K | 4.3 | Medical |
| GEMS Mobile ECGHeartCheck | 2.7K | — | Medical |
| Health & Happiness StudyAvicenna Research | 2.5K | — | Tools |
| Reliant EMUACS | 2.4K | 2.3 | Health & Fitness |
| App Usage Data Sourceethica data | 1.8K | — | Health & Fitness |
| DWELL DAILYAvicenna Research | 942 | — | Tools |
| NTR welbevindenethica data | 728 | — | Tools |
| Eleos Appethica data | 444 | — | Tools |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Life Sciences Tech | 40 | 67.2K | Avicenna 40.7K | |
| Ai In Healthcare | 13 | 4.5K | App Usage Data Source 1.8K | |
| Healthcare It | 4 | 3K | GEMS Mobile ECG 2.7K | |
| Cardiac And Vascular Disorders | 3 | 2.9K | GEMS Mobile RPM 95 | |
| Sensors | 2 | 2.5K | Reliant EMU 2.4K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 43 of 45 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
28 companies hiring · $2.45B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
The Corporation issued an aggregate of 6,404,700 Units at a price of $CAN 0.26 per Unit for aggregate gross proceeds of $CAN 1,665,222.
Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP (“Madryn”) of a short-form merger transaction, pursuant to which 100% ownership of the Company’s common stock is now consolidated under funds managed by Madryn (the “Short-form Merger”).
NetraMark Holdings Inc. (the “Company” or “NetraMark”) ... closed on February 18, 2026.
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news release dated January 19, 2026) by issuing Debentures for gross proceeds of $840,000 (the "First Tranche").
Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) announced that it has completed its previously-announced underwritten public offering of 5,168,019 common shares, which includes the exercise of the underwriters’ option to purchase an additional 712,574 common shares and pre-funded warrants to purchase 495,049 common shares.
Ventripoint Diagnostics Ltd : Announces the closing of its previously announced non-brokered private placement of an aggregate of 10,097,720 units at a price of $0.10 per Unit for aggregate gross proceeds of $1,009,772.
Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce that it has closed its previously announced equity offering for aggregate gross proceeds of approximately $12 million (the “Offering”).
Profound Medical Corp. has closed a private placement of 921,428 common shares to Canadian investors at US$7.00 per share, raising approximately US$6.45 million in gross proceeds, with the shares subject to a four-month-plus-one-day hold period under Canadian securities laws.
Quantum BioPharma Ltd. has closed a non-brokered private placement and issued 30 class A multiple voting shares at a price of $25 Per Class A Multiple Voting Shares for gross proceeds of $750.
Under the Offering, the Company issued 4,062,500 units at a price of $0.08 per unit for gross proceeds of $325,000.
Top 10 categories among 369 recorded events in the 24-month window.
6 companies with recorded IPO activity
IPO · Nasdaq Global Market2 reports
Follow-on Offering · TSX Venture Exchange2 reports
IPO · Alternative Investment Market6 reports
Follow-on Offering1 reports
Follow-on Offering · Nasdaq1 reports
SPAC · Nasdaq1 reports
13 tracked people moves
Appointment Chief Executive Officer and Chairman
Resignation Previously Executive Chairman
Appointment Chief Financial Officer
Appointment head of clinical operations
Appointment Chief Financial Officer
Resignation Previously Chief Financial Officer and Corporate Secretary
Appointment Board of Directors
Appointment Chief Development Officer and Head of Regulatory Affairs
8 recorded customer wins
Customer: Province of OntarioLife Sciences
Customer: Clinique Les Trois SoleilsHealthcare
Customer: Daiichi PharmaceuticalOncology
Customer: pfizerPharmaceuticals
Customer: Pharmaceuticals
Customer: luminexDiagnostics & Genetic Testing
1 companies with reported reductions
Scale not stated roleseconomic environment, operational efficiencies, and adaptation to technological advancements, specifically generative AI
15 recorded events
submitted for approvalChina\'s National Medical Products Administration
application pendingCanadian Securities Exchange
approved for issuing shares to satisfy interest payment obligationsTSX Venture Exchange
Device sales halted in Canada due to expired licenceHealth Canada
6 tracked suits
shareholder claim alleging improper and oppressive actionsCivil · Settled
shareholder claimCivil · Settled
Reported company results in the recorded window.
Median across 40 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Psyence→goldcoast | Announced | 2026-04-13 | Not stated in snapshot |
| madryn asset management→venus concept ↗ | Completed | 2026-03-30 | Not stated in snapshot |
| Neural Therapeutics→Hanf.com | Completed | 2025-08-29 | Not stated in snapshot |
| healwell ai→Pentavere ↗ | Completed | 2025-07-17 | $14.0M |
| Roche Holding AG→Arius Research ↗ | Announced | 2025-02-14 | Not stated in snapshot |
| trillium→Fluorinov Pharma ↗ | Announced | 2025-02-14 | $7.0M |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
89 postings in the preceding 12 months. The full 168-posting snapshot covers 54 employers.
0 tracked postings mention remote work.
36 postings specify a level.
| Company | Employees |
|---|---|
| Benchsci ↗ | 426 |
| venus concept ↗ | 384 |
| Axiom Real-Time Metrics ↗ | 330 |
| Entourage Health ↗ | 211 |
| Profound Medical ↗ | 131 |
| CIFAR ↗ | 117 |
| Deep Genomics ↗ | 105 |
| Covalon ↗ | 88 |
280 founders and chief executives across 212 companies.
Promis Tm Neurosciences, ex-Immune Pharma, ex-Dart Therapeutics, McGill University (BSc); University of Aix-Marseille, France (MD)
Ex-Microsoft Research · University of Manitoba MSc 1993, University of Toronto PhD 1997
University of Buea 2006, McMaster University MSc 2012, University of Toronto PhD 2019
University of Toronto PhD 2008
Co-Founder Asiri Skincare, ex-CEO Endo International, Bausch Health Companies, Novartis, McKinsey & Company. Princeton University BSE 1989…
Ex- CCRM, University of Toronto, Calimmune, Georgia Institute of Technology. Georgia Institute of Technology BS, University of Toronto PhD
University Health Network, Cypress Semiconductor. UWaterloo 2004, University of Toronto PhD 2010
Celestial Growth, Massachusetts Institute of Technology, 2012
3t Biosciences, ex-Stanford University, ex-Caltech, Stanford University, 2017
Novartis, ex- TxCell, Pfizer Regenerative Medicine/Neusentis, Neurospheres. The University of CalgaryBSc 1994, MSc 1996…
Spectral Medical, ex-Mjardin, ex-Growforce Holdings, The University of Western Ontario - Richard Ivey School of Business, 2002
Ex-Verio Therapeutics. York University - Schulich School of Business MBA 1984
98 profiles with education records.
2 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
3,873 articles in the measured 12-month window.
Life Sciences coverage tagged Toronto · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 1,690 |
| 2021Q3 | 1,291 |
| 2021Q4 | 875 |
| 2022Q1 | 968 |
| 2022Q2 | 977 |
| 2022Q3 | 738 |
| 2022Q4 | 804 |
| 2023Q1 | 801 |
| 2023Q2 | 1,066 |
| 2023Q3 | 963 |
| 2023Q4 | 884 |
| 2024Q1 | 1,256 |
| 2024Q2 | 1,472 |
| 2024Q3 | 1,074 |
| 2024Q4 | 1,155 |
| 2025Q1 | 3,826 |
| 2025Q2 | 726 |
| 2025Q3 | 926 |
| 2025Q4 | 1,014 |
| 2026Q1 | 1,068 |
Article volume measures coverage, not market sales.
505 recorded company events across 52 companies; percentages use that event total.
Life Sciences coverage tagged Toronto · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Canada comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| angel investors | 1,081 | 381 | 184% |
| asset acquisition | 443 | 146 | 203% |
| early-stage investment | 440 | 136 | 224% |
| vaccine candidates | 342 | 75 | 356% |
| vaccine trials | 336 | 73 | 360% |
| vaccination campaigns | 268 | 42 | 538% |
| vaccine immunogenicity | 266 | 57 | 367% |
| mass vaccination sites | 169 | 20 | 745% |
| vaccination coverage | 141 | 28 | 404% |
| vaccine effectiveness study | 137 | 29 | 372% |
| biosimilar approval | 134 | 267 | -50% |
| copa libertadores | 0 | 257 | -100% |
| biosimilar market entry | 138 | 220 | -37% |
| gene therapy rare diseases | 94 | 206 | -54% |
| biosimilar efficacy | 108 | 191 | -43% |
Canada comparison coverage
vaccine candidates, vaccine trials, vaccine immunogenicity
39.2% critical · 42.7% positiveangel investors, asset acquisition, early-stage investment
40.1% critical · 56.3% positiveearnings report, quarterly results, biosimilar market entry
31.6% critical · 46.5% positiveLife Sciences coverage tagged Toronto. Topic labels describe recorded classifications and can include broad context.
53,147 papers in the recorded worldwide scope.
Tone counts: 42,568 positive · 8,415 neutral · 2,164 negative.
Landmark: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term prob
Landmark: Genomic responses in mouse models poorly mimic human inflammatory diseases
Landmark: Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity
Common problems researchers identify · 0117.3% of this theme group
Challenges in using microbes and plant systems for biofuel, biorefinery, and nutrient recycling.
Biofuel (41) · Synthetic biology (53) · Biomass (45) · Biorefinery (28)
A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application
Biofertilizers: An ecofriendly technology for nutrient recycling and environmental sustainability
| Year | Share index |
|---|---|
| 2022 | 60.6 |
| 2023 | 59.3 |
| 2024 | 61.9 |
| 2025 | 67.0 |
Common problems researchers identify · 0216.8% of this theme group
Issues surrounding microbial hazards, processing impacts, and health implications of food products.
Food safety (130) · Food processing (74) · Food products (50) · Human health (90)
Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures
Nutritional quality and processing of plant proteins for healthy and sustainable foods
| Year | Share index |
|---|---|
| 2022 | 70.2 |
| 2023 | 72.4 |
| 2024 | 77.4 |
| 2025 | 99.2 |
Common problems researchers identify · 0315.8% of this theme group
Problems linked to mRNA therapeutics, gene expression control, and cell‑culture stability.
Messenger RNA (28) · Gene (44) · Cell culture (23) · Gene expression (24)
Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with
| Year | Share index |
|---|---|
| 2022 | 2510.1 |
| 2023 | 2495.8 |
| 2024 | 2199.0 |
| 2025 | 1697.8 |
Common problems researchers identify · 0415.4% of this theme group
Barriers to improving nutrient uptake, germplasm efficiency, and overall crop productivity.
Agriculture (208) · Crop (84) · Food security (86) · Germplasm (39)
Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants
Breeding for nutrient use efficiency in crop plants: Mechanistic insights, genetic determinants, and emerging breeding technologies
| Year | Share index |
|---|---|
| 2022 | 1635.2 |
| 2023 | 1667.4 |
| 2024 | 1799.9 |
| 2025 | 2026.9 |
Common problems researchers identify · 0515.3% of this theme group
Difficulties in controlling pathogens, pests, and integrating resistance strategies in agriculture.
Fungicide (44) · Integrated pest management (54) · Host (41) · Disease management (32)
Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens
Insect-Borne Plant Pathogens and Their Vectors: Ecology, Evolution, and Complex Interactions
| Year | Share index |
|---|---|
| 2022 | 27.8 |
| 2023 | 29.2 |
| 2024 | 27.8 |
| 2025 | 37.2 |
Common problems researchers identify · 069.9% of this theme group
Rising resistance in humans, livestock, and the environment complicates treatment options.
Antibiotic resistance (301) · Antimicrobial (164) · Antibiotics (126) · Drug resistance (49)
Antimicrobial resistance in humans, livestock and the wider environment
Antimicrobial use and resistance
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Common problems researchers identify · 079.4% of this theme group
Broad, unrelated challenges spanning biochemical order, ion regulation, and interdisciplinary topics.
Order (19) · NAD+ kinase (11) · Human being (12) · Sodium (11)
Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar
Obiteljska grupna konferencija: prilika za građansko pravosuđe?
| Year | Share index |
|---|---|
| 2022 | 18.4 |
| 2023 | 21.9 |
| 2024 | 17.8 |
| 2025 | 12.5 |
Cautions · 0121.5% of this theme group
Caution about in‑vitro and in‑vivo assays revealing oxidative damage and cytotoxic effects.
In vivo (32) · Flow cytometry (16) · In vitro (27) · Oxidative stress (19)
Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells
Cell Painting for cytotoxicity and mode-of-action analysis in primary human hepatocytes
| Year | Share index |
|---|---|
| 2022 | 1034.9 |
| 2023 | 1110.3 |
| 2024 | 911.7 |
| 2025 | 818.5 |
Cautions · 0214.6% of this theme group
Need for careful implementation of genomic tools to avoid unintended breeding outcomes.
Agriculture (45) · Selection (26) · Production (28) · Trait (16)
Genomic selection in plant breeding: from theory to practice
Future Directions for Sustainable Poultry Feeding and Product Quality: Alternatives from Insects, Algae and Agro-Industrial Fermented By-Pro
| Year | Share index |
|---|---|
| 2022 | 1437.3 |
| 2023 | 1478.4 |
| 2024 | 1637.4 |
| 2025 | 1817.4 |
Cautions · 0313.9% of this theme group
Potential risks and benefits of novel feed compounds for livestock performance and welfare.
Feed additive (27) · Animal feed (28) · Feed conversion ratio (32) · Health benefits (30)
Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production
The impact of substituting animal with plant protein foods in adults’ self-selected diets on environmental, nutritional, and health outcomes
| Year | Share index |
|---|---|
| 2022 | 22.2 |
| 2023 | 20.9 |
| 2024 | 17.3 |
| 2025 | 18.2 |
Cautions · 0413.6% of this theme group
Attention to emerging food additives, contaminants, and their compliance with safety standards.
Food safety (66) · Hygiene (21) · Contamination (29) · Food contaminant (20)
Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters
Insect-derived food colorants: Chemistry, applications, safety, and regulatory perspectives
| Year | Share index |
|---|---|
| 2022 | 91.3 |
| 2023 | 89.1 |
| 2024 | 95.4 |
| 2025 | 105.8 |
Cautions · 0513.5% of this theme group
Warnings about genomic instability, repair pathway alterations, and their impact on disease.
Gene (41) · DNA damage (26) · DNA repair (13) · Gene expression (20)
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations
Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer
| Year | Share index |
|---|---|
| 2022 | 2415.6 |
| 2023 | 2417.4 |
| 2024 | 2125.5 |
| 2025 | 1613.8 |
Cautions · 0611.7% of this theme group
Risks of using antibiotics and biocides that may select for multi‑resistant microbes.
Antibiotic resistance (59) · Antibiotics (47) · Antimicrobial (38) · Bacteria (26)
Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses
Co-Selection of Resistance to Antibiotics, Biocides and Heavy Metals, and Its Relevance to Foodborne Pathogens
| Year | Share index |
|---|---|
| 2022 | 886.3 |
| 2023 | 838.0 |
| 2024 | 911.9 |
| 2025 | 963.5 |
Cautions · 0711.3% of this theme group
Concerns over evolving pesticide resistance and the need for adaptive control strategies.
Pesticide (34) · Integrated pest management (21) · PEST analysis (30) · Biological pest control (20)
The use of fungal entomopathogens as endophytes in biological control: a review
Managing pesticide resistance by changing the applied dose: a modeling analysis incorporating pesticide persistence and including low-dose m
| Year | Share index |
|---|---|
| 2022 | 66.9 |
| 2023 | 65.3 |
| 2024 | 66.9 |
| 2025 | 75.8 |
Opportunities · 0117.4% of this theme group
Promising uses of fluorescent antibodies and flow cytometry for in‑vivo diagnostics.
Antibody (70) · In vivo (81) · Fluorescence (40) · Flow cytometry (50)
Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom
Preparation, Characterization, and Binding Mechanism of Nanobodies Targeting Multiple Serotypes of <i>Salmonella</i>
| Year | Share index |
|---|---|
| 2022 | 561.4 |
| 2023 | 615.1 |
| 2024 | 467.1 |
| 2025 | 455.3 |
Opportunities · 0217.2% of this theme group
Opportunities in targeting gene expression, knockdown, and apoptosis pathways for treatment.
Downregulation and upregulation (106) · Apoptosis (80) · Gene knockdown (103) · Cell growth (43)
Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc
RasGRP3 Promotes RAP1B Activity to Inhibit Endothelial Inflammation and Alleviate Atherosclerosis in High-Fat Diet-Fed ApoE−/− Mice
| Year | Share index |
|---|---|
| 2022 | 364.0 |
| 2023 | 394.7 |
| 2024 | 257.4 |
| 2025 | 261.8 |
Opportunities · 0314.6% of this theme group
Development of antioxidant‑rich, health‑promoting ingredients for sustainable nutrition.
Health benefits (78) · Functional food (61) · Ingredient (48) · Antioxidant (69)
Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives
PLANT-BASED PROTEINS: SOURCES, EXTRACTION METHODS AND FUNCTIONAL PERSPECTIVES FOR THE SUSTAINABLE FOOD INDUSTRY
| Year | Share index |
|---|---|
| 2022 | 26.7 |
| 2023 | 26.2 |
| 2024 | 27.1 |
| 2025 | 45.2 |
Opportunities · 0413.7% of this theme group
Innovations in DNA methylation profiling and RNA detection for disease monitoring.
Gene (164) · DNA methylation (60) · Messenger RNA (76) · DNA damage (55)
Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders
Stimuli-ResponsiveFusion of Binary-Star IntelligentDNA System for the Signal-On Amplification Detection of Cancer-RelatedmiRNA
| Year | Share index |
|---|---|
| 2022 | 2397.7 |
| 2023 | 2377.6 |
| 2024 | 2114.7 |
| 2025 | 1613.7 |
Opportunities · 0513.5% of this theme group
Exploration of plant‑derived agents and microbial metabolites to combat resistance.
Antimicrobial (126) · Antibiotic resistance (66) · Biological pest control (54) · Bacteria (87)
Plants as sources of new antimicrobials and resistance-modifying agents
Postbiotics: Multifunctional Microbial Products Transforming Animal Health and Performance
| Year | Share index |
|---|---|
| 2022 | 524.8 |
| 2023 | 510.4 |
| 2024 | 554.5 |
| 2025 | 649.8 |
Opportunities · 0611.9% of this theme group
Leveraging quantitative trait loci and selection to boost crop yields and traits.
Germplasm (71) · Trait (52) · Quantitative trait locus (40) · Selection (53)
Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield
GENETIC VARIABILITY ANALYSIS FOR YIELD AND RELATED TRAITS IN WHEAT (TRITICUM AESTIVUM L.) MUTANT GENOTYPES
| Year | Share index |
|---|---|
| 2022 | 53.0 |
| 2023 | 45.3 |
| 2024 | 39.2 |
| 2025 | 40.8 |
Opportunities · 0711.6% of this theme group
Utilizing microbial fermentation and agri‑food by‑products for eco‑friendly bioenergy.
Biomass (67) · Sustainability (77) · Agriculture (102) · Biofuel (35)
Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health
Bioactive Compounds From Agri‐Food By‐Products: Advancements in Environmental Sustainability and Bioeconomic Progress
| Year | Share index |
|---|---|
| 2022 | 1514.8 |
| 2023 | 1566.1 |
| 2024 | 1742.6 |
| 2025 | 1980.2 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Descriptive | 40.2% | 17.4% |
| Promising | 30.4% | 36.9% |
| Breakthrough | 14.1% | 26.7% |
| Problem-identifying | 8.3% | 9.7% |
| Cautionary | 3.5% | 4.6% |
| Comparative | 2.4% | 3.7% |
| Critical | 1.0% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSARS-CoV-2 wastewater genomic surveillance: approaches, challenges, and opportunities | 87 | 0.21% | 25 (28.7%) | 0.21% |
| Hardware, e-waste & supply chainFate and Transport of Antibiotic Residues and Antibiotic Resistance Genes following Land Application of Manure Waste | 61 | 0.15% | 4 (6.6%) | 0.15% |
| Bias & fairnessGeographic Prevalence Heterogeneity Creates Unavoidable Fairness-Accuracy Trade-offs in Antimicrobial Resistance Predict | 12 | 0.03% | 2 (16.7%) | 0.03% |
| Safety & misusePublic perceptions and information sources on genetically modified organisms in Kenya | 3 | 0.01% | 3 (100.0%) | 0.01% |
| Energy & datacenter footprintIntegration of GWAS and WGCNA Identifies PUE‐Related Gene <i>TaERF112</i> in Wheat | 1 | 0.0% | 0 (0.0%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
| Carbon & emissions of compute | 0 | 0.0% | 0 (%) | 0.0% |
| Labour & data work | 0 | 0.0% | 0 (%) | 0.0% |
| Concentration of compute power | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 3 September 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗